Clinical Trial Search

Primary: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8 — -15.3; -11.5 mmHg

Primary: Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks — 0.07; -0.71 percentage of glycated haemoglobin — p=0.0002

Primary: Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12 — 59.8; 65.9…

Primary: Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment — -19.9 mm Hg…

Primary: Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12) — -0.23; 0.22 HOMA-R Score

Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -28.82; -26.22 mmHg

Primary: Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8 — -29.0; -22.9 mmHg — p=0.0001

Primary: HbA1c Change From Baseline — 0.03; -0.59; -0.63 percentage of HbA1c — p=<0.0001

Primary: Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan — 33.1; 36.8 Percentage of patients

Primary: "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)" — 146; 116 Participants — p=<0.05

Primary: Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants — -5.13; -7.93; -6.05; -9.69…

Primary: Change of of Systolic Blood Pressure — -9.6; -0.7 mm Hg

Primary: Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12 — -10.40; -7.34 mm Hg — p=0.0010

Primary: Primary Major Macrovascular Events — 264; 235 participants — p=<0.05

Primary: Safety and Tolerability of Sitagliptin After 12 Weeks of Treatment — 41; 16; 8; 1 Participants

Primary: Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint — -10.3; -6.6 mmHg

Primary: Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at Week 26 — 0.12; 0.00; 0.40 Percentage

Primary: Adjusted Mean Change in HbA1c Levels — -0.38; 0.08 Percent — p=<0.0001

Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change

Primary: Changes in Systolic Blood Pressure During Initial Intralipid Infusion — 23; 13 mmHg

Primary: Changes From Baseline in Blood Pressure on Final Assessment Point (up to Week 24) Measured at the Medical Institution — -10.5; -5.1 Millimeter of Mercury (mmHg)

Primary: Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) — -11.53; -10.98; -12.45; -3.69 mmHg

Primary: Left Ventricular Torsion Defined as Change in Ventricular Mid-wall Rotation (°) Measured by Cine-Cardiac Magnetic Resonance (CMR) Imaging With Tagging, Before and After…

Primary: HbA1c Level — 6.9; 6.4 percentage of glycated hemoglobin

Primary: Flow Mediated Dilation — 6.2; 4.1 percentage of change in dilation

Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01

Primary: Absolute Change in Brachial Artery Flow-mediated Dilation (FMD). — 2.26; 1.59 percentage of brachial artery diameter

Primary: Percentage of Participants Who Had One or More Adverse Reactions — 5.41; 1.20; 0.98; 0.00 Percentage of Participants

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Month 6 — 6.79; 0.26 Percent HbA1c

Primary: Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose…